Mineralys Therapeutics (MLYS) risk factors
Item 1A of every Mineralys Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks9 new6 dropped11 reworded
Mineralys added risks concerning clinical trial adverse events, tariffs on API materials, patent validity challenges, data privacy compliance, and third-party license interpretation disputes. The company updated references from Mitsubishi to Tanabe regarding its exclusive license for lorundrostat.
Filed Mar 12, 2026 - FY2024 10-K risk factors64 risks
Mineralys Therapeutics relies entirely on the success of its sole clinical-stage product candidate, lorundrostat, for treating hypertension and related conditions. Operations depend heavily on the exclusive Mitsubishi License and require ongoing substantial capital raising and clinical trial execution.
Filed Feb 12, 2025